Highest-materiality recent filing
Kezar Life Sciences acquired by Aurinia for $6.955/sh + CVR; stock to be delisted
Tender offer expired May 8, 2026; 5,927,580 shares (80.2% of outstanding) validly tendered.
Kezar Life Sciences terminates HQ lease, separates CEO, CFO, and COO ahead of Aurinia merger
Lease for ~48,714 sq ft at 4000 Shoreline Court terminated April 1; company pays $2M ( $1.3M cash + $0.7M security deposit).
Kezar Life Sciences to be acquired by Aurinia Pharma for $6.955 per share cash plus CVR
Aurinia Pharma U.S. will commence a tender offer at $6.955/share cash plus one contingent value right (CVR) per share.
Kezar sells Sec61 assets (incl. KZR-261) to Enodia for $1M upfront, up to $127M milestones
Kezar receives $1M cash upfront ($800K at close, $200K later) for its Sec61-based discovery program and KZR-261.
Kezar fails to align with FDA on zetomipzomib trial; cuts workforce 70%, begins strategic review
Unable to align with FDA on registrational trial for zetomipzomib in autoimmune hepatitis; strategic review with TD Cowen initiated.
Kezar Life Sciences cuts 70% of workforce (~31 employees) as part of strategic review
Workforce reduction of ~31 employees (approx. 70% of total staff) announced on Nov 6, 2025.
Kezar Life Sciences ends AIH program after FDA setback, begins strategic review
FDA cancelled Type C meeting for zetomipzomib in autoimmune hepatitis; requires PK study causing ~2-year delay and 48-hour in-unit monitoring.
Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial
Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.
KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH
Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.
Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M
31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).
Kezar Life Sciences regains Nasdaq compliance as stock price holds above $1.00
Received Nasdaq Staff letter on Nov 13, 2024 confirming regained compliance.
Kezar Life Sciences reports Q3 loss $20.3M; halts PALIZADE LN trial over fatal SAEs
Net loss $20.3M ($2.78/share) vs $23.1M ($3.18) in Q3 2023; cash, equivalents and marketable securities $148.4M (Dec 31: $201.4M).
Kezar ends lupus trial after fatal SAEs, adopts poison pill to block $1.10 bid
Discontinued PALIZADE Phase 2b in lupus nephritis after 4 Grade 5 SAEs (1 placebo); 84 patients enrolled.
Kezar receives unsolicited $1.10/share acquisition proposal from Concentra Biosciences
Concentra offers $1.10 per share plus a contingent value right for 80% of net proceeds from out-licensing or disposition of Kezar's programs.
FDA clinical hold on Kezar's zetomipzomib IND for lupus nephritis after 4 fatal SAEs
FDA clinical hold on zetomipzomib IND for lupus nephritis after Kezar voluntarily suspended PALIZADE trial enrollment.
Kezar halts lupus trial after 4 deaths; IDMC recommends stop
Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.
Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).
Kezar Life Sciences stockholders reject Say-on-Pay, approve reverse split authorization
Say-on-Pay advisory vote failed: 27.2M against vs 19.8M for.
Kezar Life Sciences gets 180-day extension to regain Nasdaq minimum bid; transfers to Capital Market
Received Nasdaq notice on May 31, 2024 approving transfer to Nasdaq Capital Market and additional 180-day compliance period until Nov 25, 2024.
Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track
Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.
Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated
Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.
Kezar receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq letter Dec 1, 2023; stock closed below $1.00 for 30 consecutive business days.
Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026
Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.
Workforce reduction of ~41%, pausing all research and drug discovery; severance charge of $2.9M-$3.2M expected in Q4 2023.
Kezar licenses zetomipzomib to Everest for up to $132.5M in Greater China & SE Asia
Kezar receives $7.0M upfront; eligible for up to $132.5M in development, regulatory & commercial milestones.
Kezar Life Sciences delays KZR-261 dose expansion to 2024, still enrolling Cohort 7
Phase 1 trial of KZR-261 in solid tumors enrolling Cohort 7 (40 mg/m2); no MTD reached yet.
Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023
Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.
Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance
Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.
ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.
Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data
Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.
Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis
11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.
Chairman Jean-Pierre Sommadossi resigns; Graham Cooper appointed Chairman of Kezar Life Sciences
Jean-Pierre Sommadossi resigned as Chairman and from the Board, effective May 11, 2022, no disagreement with management.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
Max materiality 1.00 · Median 0.68 · Most common event other_material